TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, “BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC)”, has been published in Scientific Reports, a Nature Portfolio journal. This novel discovery marks a significant advancement in cold plasma technology for cancer treatment.
JCRI-ABTS’s scientists demonstrated that a combination of Canady Helios™ Cold Plasma (CHCP) and anti-BCL2A1 treatment may be beneficial and a novel therapeutic option for triple-negative breast cancer and other solid tumor cancers.
BCL2A1 expression plays an important role in cell survival after CHCP treatment in breast cancer cells and is potentially regulated by TNF-alpha. Silencing BCL2A1 by siRNA treatment or by downregulating its expression by CPI203 treatment in combination with CHCP significantly increases the potency of the CHCP treatment.
Breast cancer is the leading cause of cancer death among women. Triple-negative breast cancer (TNBC) has a very poor prognosis and frequent relapses occur early compared with other cancer subtypes. CHCP is proving to be a promising therapy for a variety of prognostically poor breast cancer types and BCL2A1 could be a potential companion diagnostic biomarker.
According to Jerome Canady, MD, Chief Science Officer, “We investigated the expression profile of 48 apoptotic and 35 oxidative gene markers after CHCP Treatment during this study, and we are pleased to report Canady Helios Cold Plasma induced cell death in the TNBC cell lines”.
Dr. Taisen Zhuang, CTO of USMI revealed, “These outstanding results, discovered by our scientists, provide the solid theoretical foundation and will boost the commercialization process of Cold Plasma Oncotherapeutics™. Patients with TNBC will benefit from our cold plasma technology in the near future”.
JCRI-ABTS and sister company USMI have recently successfully completed a Phase 1 Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (FDA IDE #G190195).
JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory focusing on Plasma Oncotherapeutics (a new cancer treatment modality) using Canady Helios™ Cold Plasma to investigate the potential of Cold Atmospheric Plasma to selectively treat cancer
About US Medical Innovations
US Medical Innovations, LLC (USMI) is a private U.S. biomedical device company and wholly-owned subsidiary of US Patent Innovations, LLC. USMI’s focus is developing advanced innovative affordable plasma and robotic electrosurgical devices and striving to develop innovative devices in the field of plasma technology for the eradication of cancer.